ERELZI sol inj 50 mg/ml 4 ser pré 1 ml

7680661750075 CH-66175 L04AB01 07.15.0.

Reimbursement limitations:

ERELZI2

Substitution préparation de référence/biosimilaire
Traitement par ERELZI exige une garantie préalable de prise en charge …

ERELZI sol inj 50 mg/ml 4 ser pré 1 ml
ERELZI sol inj 50 mg/ml 4 ser pré 1 ml
ERELZI sol inj 50 mg/ml 4 ser pré 1 ml
1 / 3
google

Details

Product number
6617502
CPT
-
Packaging group
4
Unit
Fertigspritze(n)
Composition
etanerceptum 50 mg, acidum citricum, natrii citras dihydricus, natrii chloridum, saccharum, lysini hydrochloridum, natrii hydroxidum aut acidum hydrochloridum 25 per centum, aqua ad iniectabile q.s. ad solutionem pro 1 ml corresp. natrium 3.76 mg.

Articles (1)

Erelzi 50 mg/1 ml, Injektionslösung in einer Fertigspritze
Injektionslösung
4
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
16/01/2025
Patient information leaflet
Français
16/01/2025
Patient information leaflet
Italien
16/01/2025
Professional SmPC
Allemand
16/01/2025
Professional SmPC
Français
16/01/2025
Professional SmPC
Italien
16/01/2025

Detailed composition

Substance Quantity Type Category
(N/A)
50.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
3.76 MG Substance HBESI

Authorization holder

Sandoz Pharmaceuticals AG

6343 Risch

Authorization information

Swissmedic authorization number
66175
Drug name
Erelzi, Injektionslösung in einer Fertigspritze
Galenic form
INJFS
ATC Code
L04AB01
Authorization status
Z
Dispensation category
B
First authorization
18/05/2018
Authorization expiration date
31/12/9999
IT number
07.15.0.
Domain
Human medicine
Field of application
Rheumatoide Arthritis, juvenile idiopatische Arthritis (Polyarthritis, Oligoarthritis, Psoriasis-Arthritis, Enthesitis-assoziierte Arthritis), Psoriasis-Arthritis, Morbus Bechterew (ankylosierende Spondylitis), mittelschwere bis schwere Plaque-Psoriasis

Packaging details

Description (FR)
ERELZI sol inj 50 mg/ml 4 ser pré 1 ml
Description (DE)
ERELZI Inj Lös 50 mg/ml 4 Fertspr 1 ml
Market launch
18/05/2018
Narcotic (BTM)
No

Other packaging sizes

ERELZI sol inj 25 mg/0.5ml ser pré 0.5 ml
1 FESP
View
ERELZI sol inj 25 mg/0.5ml 2 ser pré 0.5 ml
2 FESP
View
ERELZI sol inj 25 mg/0.5ml 4 ser pré 0.5 ml
4 FESP
View
ERELZI sol inj 25 mg/0.5ml 12 ser pré 0.5 ml
12 FESP
View
ERELZI sol inj 50 mg/ml ser pré 1 ml
1 FESP
View
ERELZI sol inj 50 mg/ml 2 ser pré 1 ml
2 FESP
View
ERELZI sol inj 50 mg/ml 12 ser pré 1 ml
12 FESP
View